Date: 2011-12-30
Type of information:
phase: 1
Announcement: submission of a Clinical Trial Application (CTA)
Company: Affitech (Sweden) IBC Generium (Russia)
Product: AT001/r84
Action mechanism: AT001/r84 is a new patented human monoclonal antibody to human vascular endothelial growth factor (VEGF), and is being developed as a potential treatment of cancer.
Disease: cancer
Therapeutic area: Cancer - Oncology
Country: Russia
Trial
details: The anti-VEGF antibody will be evaluated in patients with various cancers and is a possible competitor to bevacizumab (Avastin® – Roche).
Latest
news: Affitech has announced that its Russian collaboration partner, IBC Generium, has submitted a Clinical Trial Application (CTA) to the Russian Health Authority to commence a phase 1 clinical trial with Affitech’s leading antibody drug candidate AT001/r84. The anti-VEGF antibody will be evaluated in patients with various cancers and is a possible competitor to bevacizumab (Avastin® – Roche). The Phase 1 clinical trial will start as soon as the Russian CTA has been approved.
